Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 50,000 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $73.76, for a total transaction of $3,688,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.
GHDX traded down $0.31 during trading on Monday, hitting $73.12. 423,743 shares of the company traded hands, compared to its average volume of 580,289. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of 69.64 and a beta of 1.06. The firm’s fifty day moving average price is $61.67. The company has a current ratio of 5.74, a quick ratio of 5.67 and a debt-to-equity ratio of 0.17. Genomic Health, Inc. has a one year low of $50.77 and a one year high of $92.18.
Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.07. The company had revenue of $114.14 million during the quarter, compared to analyst estimates of $110.78 million. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. The firm’s revenue for the quarter was up 19.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.23 earnings per share. On average, research analysts anticipate that Genomic Health, Inc. will post 1.5 earnings per share for the current fiscal year.
GHDX has been the subject of several analyst reports. Barclays upgraded shares of Genomic Health from an “underweight” rating to an “equal weight” rating and increased their target price for the company from $45.00 to $72.00 in a report on Tuesday, July 30th. ValuEngine upgraded shares of Genomic Health from a “hold” rating to a “buy” rating in a report on Saturday, July 27th. JPMorgan Chase & Co. upgraded shares of Genomic Health from an “underweight” rating to a “neutral” rating and increased their target price for the company from $60.00 to $72.00 in a report on Monday, July 29th. Zacks Investment Research upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $77.00 target price for the company in a report on Wednesday, July 31st. Finally, Needham & Company LLC downgraded shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. Nine equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Genomic Health currently has a consensus rating of “Hold” and an average price target of $69.86.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Further Reading: What is meant by buying and selling pressure?
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.